EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Patient‐Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017–2021

Loretta A Williams iD, Cai Xu, Darcy A Ponce, Qiuling Shi iD, Melissa L Santorelli, Thomas Burke, Mehmet Altan

Cancer Medicine · 2025

DOI: 10.1002/cam4.71111 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Loretta A Williams und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Patient Reported Outcome Measures, Lung Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Understanding the symptom burden experienced by patients with cancer can enable appropriate supportive care. Our aim was to describe patient‐reported outcomes (PROs) for patients with metastatic NSCLC initiating first‐line (1L) systemic therapy under usual care at a large academic center.

Methods

Patients eligible for this prospective observational study were ≥ 18 years old when initiating 1L systemic therapy for stage IV NSCLC from January 1, 2017 to December 31, 2020. Patients completed two PRO questionnaires before 1L therapy initiation (baseline) and every ~6 weeks at imaging visits thereafter: the MD Anderson Symptom Inventory for lung cancer (MDASI‐LC) and EuroQol EQ‐5D‐5L. Study follow‐up ended on June 30, 2021.

Results

The 609 eligible patients (median age, 63 years; range, 24–87; 51% men) received 1L chemotherapy plus immunotherapy (38%), targeted therapy (29%), chemotherapy (19%), or immunotherapy (13%). The five most severe MDASI‐LC symptoms among all assessments were fatigue, pain, shortness of breath, disturbed sleep, and dry mouth; 17%–32% of assessments were rated as moderate or severe. Of all assessments, 39% recorded moderate to severe symptom interference with physical aspects of daily life, and 22% reported moderate to severe interference with affective aspects. Symptom and interference subscale scores generally declined from baseline to 102 weeks overall and for the four 1L regimens.

Conclusion

Our findings confirm previous findings that patients with a new diagnosis of metastatic NSCLC experience a moderate symptom burden. More research is needed to identify predictors and causes of this symptom burden so that it can be effectively addressed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungPatient Reported Outcome MeasuresLung NeoplasmsHumansMaleFemaleMiddle AgedAgedAged, 80 and overAdultAcademic Medical CentersProspective StudiesQuality of LifeYoung AdultAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

advanced lung cancerfirst‐line treatmentpatient‐reported outcomessymptom burdensymptom interferencesymptoms

Autor:innen und Institutionen

  • Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Value and Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Outcomes Research, MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Loretta A Williams, Qiuling Shi

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc., Rahway, NJ, USA

Zitieren

APA

Williams, L. A., Xu, C., Ponce, D. A., Shi, Q., Santorelli, M. L., Burke, T., & Altan, M. (2025). Patient‐Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017–2021. Cancer Medicine. https://doi.org/10.1002/cam4.71111

Vancouver

Williams LA, Xu C, Ponce DA, Shi Q, Santorelli ML, Burke T, et al. Patient‐Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017–2021. Cancer Medicine. 2025. doi:10.1002/cam4.71111

BibTeX
@article{Williams2025,
  author = {Williams, Loretta A and Xu, Cai and Ponce, Darcy A and Shi, Qiuling and Santorelli, Melissa L and Burke, Thomas and Altan, Mehmet},
  title = {Patient‐Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017–2021},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71111}
}
Kostenlos starten →